Molecular Pharmacology Stock Buy Hold or Sell Recommendation
| MLPH Stock | USD 0.0001 0.00 0.00% |
Given the investment horizon of 90 days and complete risk avoidance on your part, our recommendation regarding Molecular Pharmacology is 'Strong Sell'. The recommendation algorithm takes into account all of Molecular Pharmacology's available fundamental, technical, and predictive indicators you will find on this site.
Check out Molecular Pharmacology Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. In addition, we conduct extensive research on individual companies such as Molecular and provide practical buy, sell, or hold advice based on investors' investing horizon and their risk tolerance towards Molecular Pharmacology. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey.
Molecular |
Execute Molecular Pharmacology Buy or Sell Advice
The Molecular recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on Molecular Pharmacology. Macroaxis does not own or have any residual interests in Molecular Pharmacology or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute Molecular Pharmacology's advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
 |  |
Not Rated
Molecular Pharmacology Trading Alerts and Improvement Suggestions
| Molecular Pharmacology generated a negative expected return over the last 90 days | |
| Molecular Pharmacology has some characteristics of a very speculative penny stock | |
| Molecular Pharmacology has a very high chance of going through financial distress in the upcoming years | |
| Molecular Pharmacology currently holds 175.33 K in liabilities. Molecular Pharmacology has a current ratio of 0.27, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist Molecular Pharmacology until it has trouble settling it off, either with new capital or with free cash flow. So, Molecular Pharmacology's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Molecular Pharmacology sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Molecular to invest in growth at high rates of return. When we think about Molecular Pharmacology's use of debt, we should always consider it together with cash and equity. | |
| Net Loss for the year was (116.93 K) with profit before overhead, payroll, taxes, and interest of 0. | |
| Molecular Pharmacology currently holds about 1.52 K in cash with (105.41 K) of positive cash flow from operations. |
Molecular Pharmacology Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to Molecular Pharmacology or Biotechnology sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that Molecular Pharmacology's price will be affected by overall pink sheet market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a Molecular pink sheet's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over Dow Jones | 0.00 | |
β | Beta against Dow Jones | 0.00 | |
σ | Overall volatility | 0.00 | |
Ir | Information ratio | 0.00 |
Molecular Pharmacology Volatility Alert
At this time Molecular Pharmacology exhibits very low volatility. Molecular Pharmacology appears to be a penny stock. Although Molecular Pharmacology may be, in fact, a solid short-term or long term investment, many penny pink sheets are speculative investment instruments that are often subject to artificial stock promotion and campaigns of hype which may lead to misinformation and misrepresentation. Please make sure you fully understand upside potential and downside risks of investing in Molecular Pharmacology or similar risky assets. We encourage investors to look for signals such as email spams, message board hypes, claims of breakthroughs, volume upswing without any event/news,and sudden news releases. We also encourage traders to check biographies and work history of company President, CEO or other officers before investing in high-volatility instruments, penny stocks, or equities with microcap classification. You can indeed make money on Molecular instrument if you perfectly time your entry and exit. However, remember that penny pink sheets that have been the subject of artificial hype usually unable to maintain their increased share price for more than just a few days. The price of a promoted high volatility instrument will almost always revert back. The only way to increase shareholder value is through legitimate performance backed up by solid fundamentals.Molecular Pharmacology Fundamentals Vs Peers
Comparing Molecular Pharmacology's fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Molecular Pharmacology's direct or indirect competition across all of the common fundamentals between Molecular Pharmacology and the related equities. This way, we can detect undervalued stocks with similar characteristics as Molecular Pharmacology or determine the pink sheets which would be an excellent addition to an existing portfolio. Peer analysis of Molecular Pharmacology's fundamental indicators could also be used in its relative valuation, which is a method of valuing Molecular Pharmacology by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare Molecular Pharmacology to competition |
| Fundamentals | Molecular Pharmacology | Peer Average |
| Return On Asset | -5.69 | -0.14 |
| Current Valuation | 221.59 K | 16.62 B |
| Shares Outstanding | 111.55 M | 571.82 M |
| Price To Earning | (0.80) X | 28.72 X |
| EBITDA | (98.11 K) | 3.9 B |
| Net Income | (116.93 K) | 570.98 M |
| Cash And Equivalents | 1.52 K | 2.7 B |
| Total Debt | 175.33 K | 5.32 B |
| Current Ratio | 0.28 X | 2.16 X |
| Book Value Per Share | (0.02) X | 1.93 K |
| Cash Flow From Operations | (105.41 K) | 971.22 M |
| Number Of Employees | 2 | 18.84 K |
| Beta | 42.97 | -0.15 |
| Market Capitalization | 26.77 K | 19.03 B |
| Total Asset | 8.97 K | 29.47 B |
| Working Capital | (2.1 M) | 1.48 B |
| Current Asset | 9 K | 9.34 B |
| Current Liabilities | 2.11 M | 7.9 B |
| Net Asset | 8.97 K |
Molecular Pharmacology Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as Molecular . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
| Rate Of Daily Change | 1.0 | |||
| Day Median Price | 1.0E-4 | |||
| Day Typical Price | 1.0E-4 |
About Molecular Pharmacology Buy or Sell Advice
When is the right time to buy or sell Molecular Pharmacology? Buying financial instruments such as Molecular Pink Sheet isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.
Use Investing Ideas to Build Portfolios
In addition to having Molecular Pharmacology in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Israel Wall Street Thematic Idea Now
Israel Wall Street
Cross-sector collection of best publicly traded Israel entities that are expected to continue growing. The Israel Wall Street theme has 30 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Israel Wall Street Theme or any other thematic opportunities.
| View All Next | Launch |
Other Information on Investing in Molecular Pink Sheet
Molecular Pharmacology financial ratios help investors to determine whether Molecular Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Molecular with respect to the benefits of owning Molecular Pharmacology security.